找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Acute Myeloid Leukemia; Christoph Röllig,Gert J. Ossenkoppele Book 2021 Springer Nature Switzerland AG 2021 Acute Myeloid Leukemia.Genomic

[复制链接]
楼主: Capricious
发表于 2025-3-28 15:04:23 | 显示全部楼层
发表于 2025-3-28 19:52:59 | 显示全部楼层
Other Human Rights in Aviation Securityements in therapeutic options, until recently. A swathe of new drug approvals by the FDA has resulted in a subset of drugs also receiving approval in the European Union (EMA). These drugs have been discussed elsewhere in this book. This chapter will focus on new, non-immune-based therapies which hav
发表于 2025-3-29 01:23:18 | 显示全部楼层
发表于 2025-3-29 05:06:57 | 显示全部楼层
https://doi.org/10.1007/978-3-030-91194-2aNet (ELN) recommendations (Dohner et al. 2017)..This chapter intends to offer background information on germline predisposition to MN and provide the hematologist with practical guidelines on when to suspect, how to detect, and what to consider in the treatment and follow-up of patients carrying genetic predisposition to MN.
发表于 2025-3-29 10:25:48 | 显示全部楼层
Aviation Noise Impact Management presence of at least 20% of myeloid blasts in BM or PB..Careful genetic assessment, together with evaluations of performance status and comorbidities, is recommended to characterize disease-specific and patient-specific factors providing important information for risk stratification and treatment decisions.
发表于 2025-3-29 12:42:31 | 显示全部楼层
Importance of Fatigue Risk Managemente based on the probability to achieve a response to intensive or investigational salvage therapy. Several new approaches are currently evaluated and matching for controls may help to increase external validity of new approaches evaluated in single arm phase-II clinical trials.
发表于 2025-3-29 18:25:53 | 显示全部楼层
发表于 2025-3-29 19:45:32 | 显示全部楼层
发表于 2025-3-30 03:05:49 | 显示全部楼层
https://doi.org/10.1007/978-3-642-11703-9able safety profile as compared to what we have learned so long with intensive chemotherapy in R/R AML. Other small molecules targeting BCL2 or TP53, drug combinations, or monoclonal antibodies are also intensively studied in these patients paving the way for significant prognosis improvement in the coming years.
发表于 2025-3-30 05:51:33 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-11 02:21
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表